Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06430788 · ClinicalTrials.gov registry record · Phase 2
A Study of Emapalumab for Pediatric Aplastic Anemia
A Phase 2 study of Aplastic Anemia and Cytopenia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 6
- Study locations
NCT06430788 is a Phase 2 study of Aplastic Anemia and Cytopenia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants, below the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (15% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06430788, a Phase 2 study of Aplastic Anemia and Cytopenia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
Conditions Studied
Interventions
- BIOLOGICAL Emapalumab
Study Locations (6)
Wisconsin
- Children's Hospital of Wisconsin (Data Collection Only) - Milwaukee
- Medical College of Wisconsin (Data Collection AND Data Analysis) - Milwaukee
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Ohio
- Cincinnati Children's Hospital Medical Center (Data collection only) - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis) - Philadelphia
Virginia
- Virginia Commonwealth University (Data Collection Only ) - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2029-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06430788
The ClinicalTrials.gov registry entry for NCT06430788 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (15% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Aplastic Anemia appearing as the primary indexed condition, and to 1 intervention - of which Emapalumab is the first listed.
NCT06430788 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Wisconsin, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT06430788 about?
NCT06430788 is a clinical study titled "A Study of Emapalumab for Pediatric Aplastic Anemia". The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
What is the current status of trial NCT06430788?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2024-05-21. Estimated completion is 2029-05-21.
What conditions does trial NCT06430788 study?
This clinical trial studies the following conditions: Aplastic Anemia, Cytopenia, Hypocellular Marrow.
What interventions are being tested in trial NCT06430788?
The interventions under investigation include: Emapalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06430788?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06430788 being conducted?
This trial has 6 study locations across New York, Ohio, Pennsylvania, Virginia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
RECRUITING · Phase 2
-
Haploidentical HCT for Severe Aplastic Anemia
RECRUITING · Phase 2
-
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.